Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: HAE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $84.55
1 Year Target Price $84.55
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.83% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.90B USD | Price to earnings Ratio 23.67 | 1Y Target Price 84.55 |
Price to earnings Ratio 23.67 | 1Y Target Price 84.55 | ||
Volume (30-day avg) 10 | Beta 0.36 | 52 Weeks Range 47.32 - 85.61 | Updated Date 12/1/2025 |
52 Weeks Range 47.32 - 85.61 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 1.11 | Actual 1.27 |
Profitability
Profit Margin 12.67% | Operating Margin (TTM) 21.02% |
Management Effectiveness
Return on Assets (TTM) 6.36% | Return on Equity (TTM) 19.47% |
Valuation
Trailing PE 23.67 | Forward PE 17.15 | Enterprise Value 4736268817 | Price to Sales(TTM) 2.94 |
Enterprise Value 4736268817 | Price to Sales(TTM) 2.94 | ||
Enterprise Value to Revenue 3.57 | Enterprise Value to EBITDA 13.27 | Shares Outstanding 46809672 | Shares Floating 46219870 |
Shares Outstanding 46809672 | Shares Floating 46219870 | ||
Percent Insiders 1.18 | Percent Institutions 113.44 |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics was founded in 1971. It has evolved from a blood processing solutions company to one offering a broader range of medical devices and services, including blood and plasma collection, transfusion management, and hemostasis management.
Core Business Areas
- Plasma: Offers automated plasma collection systems and software solutions used by plasma collection centers. This segment is a significant revenue driver.
- Blood Center: Provides solutions for blood donation, processing, and storage, including automated collection systems and pathogen reduction technologies.
- Hospital: Focuses on solutions for blood management in hospitals, including point-of-care hemostasis analyzers and transfusion management systems.
Leadership and Structure
Haemonetics is led by a CEO and executive management team. The organizational structure includes functional departments such as sales, marketing, research and development, and operations. The Board of Directors oversees the company's governance.
Top Products and Market Share
Key Offerings
- NexSys PCS: Automated plasma collection system, is a primary product in the Plasma segment. It is designed to improve the efficiency and safety of plasma collection. Competitors include Terumo BCT and Grifols.
- Cell Saver Elite+: Autotransfusion system used in hospitals to recover and reinfuse a patient's own blood during surgery, reducing the need for donor blood. Competitors include LivaNova and Medtronic.
- TEG Hemostasis Analyzer: Point-of-care diagnostic device used to assess a patient's coagulation status. It aids in guiding transfusion decisions and managing bleeding risks. Competitors include Instrumentation Laboratory (Werfen) and Roche Diagnostics.
Market Dynamics
Industry Overview
The market for blood management and hemostasis solutions is driven by factors such as the increasing demand for blood and plasma products, advancements in medical technology, and the growing focus on patient blood management strategies.
Positioning
Haemonetics holds a significant position in the plasma collection and hospital blood management markets. Its competitive advantages include its established customer base, innovative technology, and global presence.
Total Addressable Market (TAM)
The total addressable market for blood management and plasma collection solutions is estimated to be in the billions of dollars. Haemonetics has a strong position within this market and continues to pursue opportunities to expand its market share.
Upturn SWOT Analysis
Strengths
- Strong market position in plasma collection
- Innovative product portfolio
- Global presence and distribution network
- Established customer relationships
- Recurring revenue streams
Weaknesses
- Dependence on plasma collection market
- Competition from larger medical device companies
- Fluctuations in raw material costs
- Product recalls
Opportunities
- Expanding into emerging markets
- Developing new applications for existing technologies
- Acquiring complementary businesses
- Partnering with healthcare providers
- Increasing adoption of patient blood management programs
Threats
- Regulatory changes
- Economic downturns
- Technological obsolescence
- Increased competition
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- TER (Terumo Corp)
- GRFS (Grifols SA)
- BDX (Becton Dickinson)
Competitive Landscape
Haemonetics competes with a range of companies, from large medical device manufacturers to smaller specialized firms. It differentiates itself through its focus on blood management and hemostasis solutions, as well as its strong customer relationships.
Major Acquisitions
Cardiva Medical, Inc.
- Year: 2021
- Acquisition Price (USD millions): 510
- Strategic Rationale: Expanded Haemonetics' portfolio of vascular closure systems and strengthened its position in the interventional cardiology market.
Growth Trajectory and Initiatives
Historical Growth: Haemonetics has experienced growth through organic product development and strategic acquisitions.
Future Projections: Analysts project continued growth for Haemonetics, driven by the increasing demand for plasma and blood products, as well as the company's expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of new products, expansion into new geographic regions, and acquisitions of complementary businesses.
Summary
Haemonetics is a significant player in the blood management and hemostasis solutions market, particularly in plasma collection. Its strengths lie in its innovative products, global presence, and established customer base. However, it faces competition from larger medical device companies and is subject to regulatory and economic risks. The company's growth prospects are tied to the increasing demand for blood and plasma products and its ability to expand into new markets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.